The study did meet the primary PFS primary end point; the median PFS for dato-DXd is 6.9 months vs 4.9 months in the ...
Trastuzumab deruxtecan (T-DXd) significantly improves IDFS over trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer post-neoadjuvant therapy. The DESTINY-Breast05 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback